Peritoneal dialysis (PD) is a well-accepted therapeutic strategy for patients with end-stage renal disease. However, long-term PD is limited because of peritoneal fibrosis in response to chronic infusion of the bioincompatible PD fluid (PDF). After long-term exposure to PDF, the peritoneum undergoes histological changes including a loss of mesothelial cell monolayer accompanied by excessive deposition of extracellular matrix and angiogenesis. 1, 2 Although targeting fibrosis and/or angiogenesis with antisense or peptide reagents have been shown to inhibit peritoneal fibrosis, [3] [4] [5] specific and effective anti-fibrosis therapies in PD remain to be explored.
Mounting evidence shows that TGF-b1 plays a pivotal role in the development of PD-related peritoneal fibrosis. Persistent elevation of TGF-b1 in effluents from PD patients with frequent peritonitis is associated with increased risk for peritoneal fibrosis. 6 Overexpression of TGF-b1 using adenovirusmediated gene transfer in rat peritoneum recapitulates the structural and functional changes observed in patients with PD. 7, 8 In contrast, inhibition of TGF-b1 ameliorates the damage to the peritoneum in different animal models. 9 It is well established that Smads are key intracellular effectors of TGF-b signaling and Smad3, but not Smad2, is an essential mediator in TGF-b1-induced renal fibrosis. 10, 11 Similarly, it has been reported that deletion of Smad3 protects against peritoneal fibrosis. 12 However, as TGF-b/Smad3 is indispensable in maintaining homeostasis of the immune system, 13, 14 it raises concerns about long-term consequences to treat fibrosis by blocking the general effects of this pathway. Thus, targeting the TGF-b/Smad3-related gene(s) associated with fibrosis may represent a better therapy approach for treatment of peritoneal fibrosis.
MicroRNAs (miRNAs) are small regulatory RNAs that may have important roles in a wide range of pathophysiological processes. Recent findings indicated that the miR-29 family is one of the best characterized miRNAs related to TGF-b1-mediated fibrosis. 15 Indeed, miR-29 is predicted to target a multitude of extracellular matrix genes, such as ELN, FBN1, COL1A1, COL1A2, and COL3A1. 16 Thus, loss of miR-29 contributes to fibrosis in the heart, liver, and lung diseases. [16] [17] [18] [19] We and other investigators also identify that miR-29b is a target gene of TGF-b/Smad3 and overexpression of miR-29b is capable of inhibiting TGF-b/Smad3-mediated fibrosis in the heart, lung, and kidney diseases. 17, [20] [21] [22] [23] However, it remains unknown whether miR-29 has therapeutic effect on peritoneal fibrosis. Therefore, the present study examined if miR-29 has therapeutic potential for peritoneal fibrosis in a mouse model of PD.
MATERIALS AND METHODS
Gene Transfer of Inducible MiR-29b into the Peritoneum via an Ultrasound-Microbubble-Mediated System A Dox-regulated miR-29b-expressing plasmid pTRE 2 -miR-29b was generated as previously reported. 17 The empty vector (EV) pTRE 2 -hygro was used as a control. To achieve Dox-induced transgene expression, pTRE 2 -miR-29b/pTRE 2 -hygro and pEFpuro-p-Tet-on were co-transfected into the abdominal cavity via an ultrasound-microbubble delivery system as described previously with some modifications. 24, 25 Briefly, a mixture of plasmids (pTRE 2 -miR-29b or pTRE 2 -hygro EV) and Sonovue (Bracco Diagnostics, Princeton, NJ, USA) was prepared with 1:1 vol/vol ratio. Then the mixed solution containing 200 mg of designated plasmids in total volume of 1 ml was immediately injected into the peritoneal cavity. The ultrasound probe (Sonitron 2000; Rich-Mar Corp., Inola, OK, USA) was placed vertically to the anterior abdominal surface and moved over the entire anterior abdominal wall to allow the ultrasound beam to reach the whole peritoneum. The ultrasound treatment was performed at 1 MHz input frequency and 2 W/cm 2 output intensity for 5 min. To induce miR-29b transgene expression, a dose of Dox (300 ml) with a concentration of 200 mg/ml was administered into the peritoneal cavity just after ultrasound exposure and followed by 200 mg/ml of Dox in the daily drinking water over the entire study period. The same protocol was applied to mice treated with either control or miR-29b plasmids.
Animal Experimental Protocol
Male C57BL/6J mice (8-10-weeks old) purchased from Laboratory Animal Services Centre, the Chinese University of Hong Kong, were used in this study. A mouse model of peritoneal fibrosis was induced by daily intraperitoneal injection of 3 ml of 4.25% dextrose PDF (Baxter HealthCare, Deerfield, IL, USA) as previously described with some modifications. 24 We first performed pilot studies to determine miR-29b transfection rate and transgene expression in the peritoneal tissues. Groups of three to four mice treated with ultrasound-mediated pTRE 2 -miR-29b plasmids were killed at 1, 2, 3, and 4 weeks after ultrasound treatment. Consistent with our previous finding in heart and kidney diseases, 17,21 a significant higher level of miR-29b expression was observed at the first 2 weeks after miR-29b gene transfer. Thus, a second ultrasound-microbubble-miR-29b treatment was given at day 14 in the experiment over 28 days.
Two experiments were conducted in this study. First, to examine the protective role of miR-29b in peritoneal fibrosis, groups of six mice were treated with ultrasound-mediated pre-miR-29b or control EVs gene transfer (termed day 0), followed immediately by daily PDF infusion. All mice were given the second ultrasound-microbubble-miR-29b or control treatment at day 14 and killed at day 28. Second, to determine the therapeutic potential of miR-29b in peritoneal fibrosis, groups of six mice were treated with pre-miR-29b or control plasmids at day 14 after PD and killed at day 28. In addition, groups of six mice under PD but without treatment were killed at day 14 and day 28 as untreated-disease controls. All experimental procedures were approved by the Animal Experimentation Ethics Committee at the Chinese University of Hong Kong.
Peritoneal tissues including the anterior abdominal wall and omentum were collected, fixed in methyl Carnoy's for histology and immunohistochemistry or snap-frozen for RNA and protein extraction. For in situ hybridization, the anterior abdominal wall was fixed in 4% paraformaldehyde solution.
Analysis of Peritoneal Permeability
Modified peritoneal equilibration tests were performed to determine the peritoneal permeability before the mice were killed. After intraperitoneal injection of 3 ml of 4.25% dextrose of PDF, dialysate and blood samples were collected at 0 and 120 min of dwell time. The concentrations of glucose and BUN in the dialysate and plasma were measured using commercial kits (Stanbio Laboratory, Boerne, TX, USA). The peritoneal permeability was determined by the absorption of glucose from the dialysate (D/D0) and the dialysateto-plasma (D/P) ratio of blood urea nitrogen.
RNA Extraction, Quantitative Real-Time PCR, and In Situ Hybridization Total RNA was extracted from peritoneal tissues using Tri-Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Real-time PCR for miR-29b was performed using the TaqMan microRNA assay kit (Applied Biosystems, Foster City, CA, USA) and Bio-Rad iQ SYBR Green supermix with Opticon2 (Bio-Rad, Hercules, CA, USA). The primers used in this study including mouse miR-29b, U6, collagen I, a-SMA, b-actin, and TGF-b1 were described previously. [20] [21] [22] The housekeeping genes U6 and b-actin were used as internal controls. The ratio for the mRNA of interest normalized with internal controls was expressed as mean ± s.e.m.
For in situ hybridization, specific LNA-digoxigenin-labeled mmu-miR-29b probe (5 0 -AACACTGATTTCAAATGGTG CTA-3 0 ) or scramble control probe (5 0 -GTGTAACAC GT CTATACGCCCA-3 0 ) were purchased from Exiqon (Vedbaek, Denmark). In situ hybridization of miR-29b was performed in paraformaldehyde-fixed, paraffin-embedded peritoneal sections as described previously. [20] [21] [22] Histology, Immunohistochemistry, and Two-Color Immunofluorescence All histological and immunohistochemical analyses were performed on methyl Carnoy's-fixed, paraffin-embedded sections. Deparaffinized sections of the anterior abdominal wall were stained with Masson's trichrome stain kit (ScyTek Laboratories, Logan, UT, USA) to quantify fibrosis. The thickness of the submesothelial collagenous zone was determined under microscope in coded slides using a metric ocular and was expressed as the mean of 10 independent measurements for each mouse section. Immunohistochemistry was carried out using a microwave-based antigen retrieval technique. 26 The primary antibodies used in this study included collagen I (SouthernBiotech, Birmingham, AL, USA), a-SMA (Sigma), CD31, VEGF, p-Smad2/3, and TGFb1 (Santa Cruz Biotechnology, Dallas, TX, USA). CD31-positive blood vessels in the omentum and p-Smad2/3-positve cells in the anterior abdominal wall were counted under high power fields by means of a graticule fitted in the eyepiece of the microscope and expressed as positive vessels/mm 2 or positive cells/high power field. Percentages of VEGF-positive area in the omentum were quantified by the Image-Pro plus 7.0 software (Media Cybernetics, Bethesda, MD, USA) as reported previously. [20] [21] [22] TGF-b1 expression in the anterior abdominal wall was semiquantitatively analyzed based on positive staining intensity: 0 ¼ no staining, 1 ¼ mild, 2 ¼ moderate, 3 ¼ strong staining. All quantitative analyses were performed in coded slides and 10 consecutive high power fields were assessed for each mouse section. A mean value from 10 independent measurements was calculated for statistical analysis.
To examine epithelial-to-mesenchymal transition (EMT) during peritoneal fibrosis, two-color immunofluorescence was performed on the snap-frozen peritoneal tissue sections. Sections were incubated with Cy3-conjugated antibody against a-SMA(Sigma) and a rabbit anti-mouse cytokeratin (Santa Cruz Biotechnology) for overnight at 4 1C, followed by the goat anti-rabbit FITC-conjugated IgG (Dako, Glostrup, Denmark) for 1 h. Nuclei were counterstained with DAPI. The EMT cells were identified by co-expressing a-SMA (red) and cytokeratin (green) antigens under fluorescent microscope (Axioplan2 imaging, Carl Zeiss, Oberkoche, Germany).
Western Blot Analysis
Protein from peritoneal tissues was extracted as previously reported. [20] [21] [22] The primary antibodies used in this study included collagen I (SouthernBiotech), E-cadherin (BD Transduction Laboratories, San Jose, CA, USA), a-SMA (Dako), Sp1, and b-actin (Santa Cruz Biotechnology). The signals were detected by the LiCor/Odyssey infrared image system (LI-COR Biosciences, Lincoln, NE, USA) and quantified by Image J software (National Institutes of Health). The ratio for the protein of interest was normalized against b-actin and expressed as mean ± s.e.m.
Statistical Analysis
Data from this study were expressed as mean ± s.e.m. Statistical analyses were performed using one-way analysis of variance, followed by Newman-Keuls Post Test from the GraphPad Prism 5.0 software (San Diego, CA, USA).
RESULTS

MiR-29b Gene Transfer Prevents Peritoneal Fibrosis in a Mouse Model of Peritoneal Dialysis
It is known that within the miR-29 family, miR-29a is co-expressed with miR-29b-1 and miR-29c is co-expressed with miR-29b-2. 16 Thus, miR-29b is a representative miRNA of the miR-29 family and was used in this study. We first examined the efficiency of ultrasound-microbubble-mediated miR-29b transgene expression in the peritoneum. By in situ hybridization, we detected that moderate miR-29b was constitutively expressed by peritoneal mesothelial cells and cells in the submesothelial area and muscles in the anterior abdominal wall in normal mice, but this was largely decreased in the fibrotic peritoneum after PDF for 28 days (Figure 1a ). In contrast, PD mice that were given miR-29b gene transfer exhibited a strong expression of miR-29b in the peritoneal tissues including mesothelial cells and fibroblastlike cells in the submesothelial area ( Figure 1a) . Quantitative real-time PCR analysis of the omentum tissues confirmed this finding ( Figure 1c) .
Next we examined the preventive effect of miR-29b on peritoneal fibrosis and functional injury in response to the chronic PDF infusion. Masson's trichrome staining revealed that compared with normal mice, mice on PD receiving no treatment or control EVs showed a typical feature of peritoneal fibrosis, including loss of the mesothelial cell monolayer and the thickening of submesothelial compact zone within the anterior abdominal wall (Figure 1b and d) . These histological changes were associated with the increased peritoneal permeability as determined by peritoneal equilibration tests (Figure 1e and f) . In contrast, miR-29b transfer prevented the peritoneal thickening and excessive matrix deposition as well as peritoneal dysfunction (Figure 1 ). These protective effects on peritoneal fibrosis were further demonstrated by the ability of overexpressing miR-29b to inhibit collagen I expression at both protein and mRNA levels (Figure 2a-c) and to block EMT by restoration of E-cadherin whereas significantly inhibiting a-SMA expression and cytokeratin þ a-SMA þ cells in the thickened peritoneum (Figure 2d-g ). Furthermore, we also found that overexpression of miR-29b largely inhibited peritoneal angiogenesis by significantly reducing CD31-positive blood vessels and expression of VEGF in the fibrotic peritoneal tissues (Figure 3 ).
MiR-29b Gene Transfer Retards Progressive Peritoneal Fibrosis in a Mouse Model of Established PD
We then examined whether miR-29b has therapeutic effect on peritoneal fibrosis in a mouse model of established PD. Realtime PCR showed that a daily injection of PDF for 14 days resulted in the reduction of miR-29b expression, becoming almost lost by day 28 (Figure 4a ). Reduced peritoneal miR-29b expression at day 14 was associated with the development of a EMT was also evident at day 14 as shown by partial loss of E-cadherin whereas increasing a-SMA expression and the appearance of cytokeratin þ a-SMA þ cells in the thickened peritoneum (Figure 5e-g ). These changes worsened by day 28, but were attenuated by the treatment with miR-29b over day 14 to 28 ( Figures 4 and 5) . Of note, miR-29b treatment from day 14 onward was able to halt the progression of peritoneal fibrosis, but did not reverse the severity of peritoneal injury when compared with the disease parameters at day 14 before treatment ( Figures 4 and  5) . Interestingly, while pre-treatment of miR-29b significantly inhibited peritoneal angiogenesis and peritoneal dysfunctions (Figures 1 and 3 ), delayed treatment with miR-29b at day 14 after PD produced only a partially inhibitory effect on peritoneal angiogenesis and peritoneal functional injury (Figures 4 and 6) .
Blockade of the Sp1-TGF-b/Smad Signaling is a Mechanism by which miR-29b Inhibits Peritoneal Fibrosis
Finally, we explored potential mechanisms whereby miR-29b inhibits peritoneal fibrosis. Immunohistochemical and real- time PCR analysis revealed that loss of miR-29b in fibrotic peritoneal tissues was associated with a marked activation of TGF-b/Smad signaling identified by a numerous phosphorylated Smad2/3-positive cells and a marked upregulation of TGF-b1 within the thickened peritoneum (Figures 7 and 8,  a-d) . In contrast, gene transfer with miR-29b before or after the established PD resulted in a significant inhibition of TGF-b1 expression and activation of Smad2/3 in the peritoneal tissues (Figures 7 and 8, a-d) .
It is known that a transcription factor specificity protein 1(Sp1) plays an important role in TGF-b-induced collagen synthesis and is a putative target of miR-29b. 27 ,28 Thus, we further tested a hypothesis that miR-29b may inhibit peritoneal fibrosis via a mechanism of the Sp1-TGF-b/ Smad pathway. Western blot analysis revealed that expression of Sp1 was significantly upregulated in the fibrotic peritoneal tissues after PD (Figures 7 and 8, e,f) . In contrast, treatment with miR-29b before or after PD produced an inhibitory effect on expression of Sp1 ( Figures  7 and 8, e,f) .
DISCUSSION
The present study identified that PD-related peritoneal fibrosis was associated with a loss of miR-29b, whereas overexpression of miR-29b before or after PD was capable of preventing or intervening progressive peritoneal fibrosis and functional injury. Results from this study suggested that miR29b may play a protective role and has therapeutic potential for PD-associated peritoneal fibrosis.
Consistent with the previous finding that miR-29 is a key player in a variety of disease models associated with fibrosis, including postmyocardial and hypertensive remodeling, 16,17 versus PDF-treated mice at day 14. UT, untreated PD mice; EV, empty vector control. Scale bar ¼ 50 mM.
miR-29 inhibits peritoneal fibrosis J-W Yu et al liver cirrosis, 18 pulmonary fibrosis, 19, 20 and obstructive and diabetic nephropathy, [21] [22] [23] the present study added new evidence for a protective and therapeutic role of miR-29b in PD-related peritoneal fibrosis. This was supported by the finding that PDF-induced peritoneal fibrosis was associated with a loss of peritoneal miR-29b, whereas, restored In the present study, we also demonstrated that blockade of the Sp1-TGF-b/Smad pathway may be a mechanism by which miR-29b attenuated peritoneal fibrosis. In peritoneal tissues with severe fibrosis, loss of miR-29b was associated with upregulation of Sp1 and TGF-b1 and activation of Smad2/3, suggesting the link between miR-29 and Sp1-TGF- We have previously shown that Smad3 binds the promoter of miR-29b to negatively regulate miR-29b expression in response to TGF-b1 during renal fibrosis. 22 It is also possible that a marked activation of TGF-b/Smad3 signaling in the fibrotic peritoneal tissues may downregulate miR-29b, resulting in progressive peritoneal fibrosis. There were several mechanisms whereby miR-29b may inhibit peritoneal fibrosis. First, it is well established that miR-29 suppresses fibrogenesis by directly targeting the 3'UTRs of COL1A1, COL1A2, COL3A1, ELN, and FBN1. 16 Therefore, overexpression of miR-29b in the peritoneal tissue may repress the expression of collagen matrix directly. Second, miR-29 may exert its anti-fibrosis effect by inhibiting TGF-b1 transcription. 29 A recent identification of miR-29b to directly target the coding sequence of TGF-b1 on Exon 3 supports this mechanism. 17 It is now well established that TGF-b/ Smad signaling plays a functional role in the pathogenesis of peritoneal fibrosis because overexpression of TGF-b1 in the peritoneum induced EMT, 8 whereas inhibition of this pathway by overexpressing an inhibitor Smad7 is capable of attenuating peritoneal fibrosis in rat models of PD. 24, 30 Thus, blockade of TGF-b/Smad-mediated peritoneal fibrosis may be a central mechanism by which miR-29b inhibited peritoneal fibrosis including EMT. In addition, as a putative target of miR-29, 28 Sp1 has been implicated in TGF-b1-induced collagen synthesis and the interaction between Sp1 and Smad3 has been shown to enhance the TGF-b-induced fibrotic response. 27, 31 Therefore, blockade of the Sp1-Smad3 interaction may be another mechanism accounting for the ability of overexpressing miR-29b to inhibit TGF-b/Smad3-mediated peritoneal fibrosis.
Inhibition of peritoneal angiogenesis may also contribute to the inhibitory effect of miR-29b on peritoneal fibrosis and peritoneal dysfunction. In patients with PD, a significant correlation between increased peritoneal vascular density and peritoneal fibrosis has been noticed and increased expression of VEGF has been reported in both dialysis solutions and peritoneal tissues. 32, 33 Consistent with these findings, the present study also showed that expression of peritoneal VEGF and CD31 þ vessels were largely increased in response to chronic infusion of PDF, which was associated with progressive peritoneal fibrosis and deterioration of peritoneal functions. Treatment with miR-29b before PD produced a significant inhibitory effect on peritoneal angiogenesis and improvement of peritoneal function; however, delayed miR-29b treatment at day 14 after PD produced a less inhibitory effect on angiogenesis, which may explain a notion that peritoneal functional injury was not significantly improved when miR-29b treatment was delayed. Although mechanisms whereby miR-29b inhibited angiogenesis remain largely unknown, it is likely that miR-29b may act by blocking TGF-b/Smad signaling to suppress angiogenesis because TGF-b1 is a well-known angiogenesis factor capable of promoting VEGF expression and angiogenesis. 7, 34 In addition, as EMT is responsible for high solute transport rate in PD patients, 35 inhibition of EMT may also be a mechanism by which miR-29b treatment improves peritoneal dysfunctions.
The present study also demonstrated that the non-invasive ultrasound-microbubble technique may be a convenient and effective method for miRNA therapy in peritoneal diseases. We have previously shown that the ultrasound-microbubble technique is able to deliver a Dox-inducible Smad7 to block TGF-b/Smad-mediated peritoneal fibrosis. 24, 30 In the present study, we provided further evidence that this non-invasive ultrasound-based technique was also an effective method to deliver miRNA plasmids into the peritoneal tissues. By using this technique, we were able to effectively but non-selectively transfect the pre-miR-29b into the peritoneal tissues, thereby inhibiting peritoneal fibrosis induced by PD. Although it remains largely unclear, the mechanism by which ultrasoundmediated miR-29b gene transfer may largely be attributed to the local ultrasound-mediated miR-29b-bearing microbubble cavitation. Indeed, the cavitation can also cause a transient formation of small holes (o5 mm) on the cell surface, 36 which may largely enhance the released gene entering into the peritoneal cells, resulting in inhibition of peritoneal fibrosis.
In conclusion, the present study identifies that after longterm exposure to PDF, peritoneal fibrosis occurs with a loss of miR-29b. In contrast, overexpression of miR-29b is capable of inhibiting PD-associated peritoneal fibrosis and improving peritoneal dysfunction. Blockade of the Sp1-TGF-b/Smad pathway may be a mechanism by which overexpression of miR-29b inhibits peritoneal fibrosis. Results from this study suggest that treatment with miR-29b may represent as a novel and effective therapy for PD-related peritoneal fibrosis.
